Anti-PD-1/PD-L1 mAbs also showed benefit over chemotherapy in overall survival (OS) and PFS of patients with non-small cell lung cancer (NSCLC), supported by convincing evidence and suggestive evidence, respectively. The gene discussed is CD274; the disease is non-small cell lung carcinoma.